geographic atrophy

APL-2 slows growth of GA in phase II safety and efficacy trialTwelve-month results of the FILLY trial show that in patients with geographic atrophy, the administration of complement C3 inhibitor APL-2 slowed the growth rate of the disease. It also appeared to increase the risk of new onset AMD, although this did not have an adverse effect on visual outcomes.
Intravitreal brimonidine holds promise for slowing GA growthBrimonidine Drug Delivery System (Brimo DDS) in an intravitreally administered, sustained-release implant (Allergan) shows promise as a treatment for geographic atrophy (GA), secondary to age-related macular degeneration in a phase IIa clinical trial.
AO imaging offers novel data for understanding retinal diseaseAdaptive optics (AO) is providing new insights about retinal structure and may help to identify potential areas for treatment of retinal diseases, said Mina Chung, MD.
Ultra-widefield camera captures images from macula, far peripheryA recently released ultra-widefield fundus camera takes images in true color and captures high-resolution imagess rom the macula to the far periphery.
What you missed at AAO in Anaheim
What you missed at AAO in AnaheimScientific research, new products, and industry announcements kicked off the 95th annual meeting of the American Academy of Optometry (AAO)
Pipeline for dry AMD features diverse compoundsA number of drugs are being investigated in clinical trials as treatment for slowing the growth of geographic atrophy that is secondary to age-related macular degeneration.
Do more anti-VEGF injections lead to better clinical outcomes?The appropriate use of agents that inhibit vascular endothelial growth factor (VEGF) can bring significant improvements to both short-term and long-term visual acuity for patients with neovascular AMD.
New prevention and monitoring strategies for neovascular AMDNutritional supplements continue to be a viable prevention strategy for neovascular age-related macular degeneration (AMD), said Emily Chew, MD.
Functional reading scores useful for geographic atrophyBest-corrected visual acuity does not capture the degree of impairment in some patients, such as those with geographic atrophy, particularly as they try to read across a page. A new patient-reported outcome measure has been found to correlate well with a more objective measurement of performance.
Erythropoietin appears effective in stabilizing dry AMDThe neuroprotective effects of intraocular treatment with erythropoietin in the reduction of geographic atrophy progression and vision loss were reviewed in an off-label study.